Literature DB >> 33945498

An Overview of the Treatment Options Used for the Management of COVID-19 in Pakistan: Retrospective Observational Study.

Hashaam Akhtar1, Samar Akhtar1, Fazal-Ul Rahman2, Maham Afridi3, Sundas Khalid4, Sabahat Ali5, Nasim Akhtar6, Yousef S Khader7, Hamaad Ahmad1, Muhammad Mujeeb Khan8.   

Abstract

BACKGROUND: Since the first reports of COVID-19 infection, the foremost requirement has been to identify a treatment regimen that not only fights the causative agent but also controls the associated complications of the infection. Due to the time-consuming process of drug discovery, physicians have used readily available drugs and therapies for treatment of infections to minimize the death toll.
OBJECTIVE: The aim of this study is to provide a snapshot analysis of the major drugs used in a cohort of 1562 Pakistani patients during the period from May to July 2020, when the first wave of COVID-19 peaked in Pakistan.
METHODS: A retrospective observational study was performed to provide an overview of the major drugs used in a cohort of 1562 patients with COVID-19 admitted to the four major tertiary-care hospitals in the Rawalpindi-Islamabad region of Pakistan during the peak of the first wave of COVID-19 in the country (May-July 2020).
RESULTS: Antibiotics were the most common choice out of all the therapies employed, and they were used as first line of treatment for COVID-19. Azithromycin was the most prescribed drug for treatment. No monthly trend was observed in the choice of antibiotics, and these drugs appeared to be a random but favored choice throughout the months of the study. It was also noted that even antibiotics used for multidrug resistant infections were prescribed irrespective of the severity or progression of the infection. The results of the analysis are alarming, as this approach may lead to antibiotic resistance and complications in immunocompromised patients with COVID-19. A total of 1562 patients (1064 male, 68.1%, and 498 female, 31.9%) with a mean age of 47.35 years (SD 17.03) were included in the study. The highest frequency of patient hospitalizations occurred in June (846/1562, 54.2%).
CONCLUSIONS: Guidelines for a targeted treatment regime are needed to control related complications and to limit the misuse of antibiotics in the management of COVID-19. ©Hashaam Akhtar, Samar Akhtar, Fazal-Ul Rahman, Maham Afridi, Sundas Khalid, Sabahat Ali, Nasim Akhtar, Yousef S Khader, Hamaad Ahmad, Muhammad Mujeeb Khan. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 27.05.2021.

Entities:  

Keywords:  COVID-19; Pakistan; antibiotic resistance; antibiotics; first wave; multidrug resistant infections

Year:  2021        PMID: 33945498     DOI: 10.2196/28594

Source DB:  PubMed          Journal:  JMIR Public Health Surveill        ISSN: 2369-2960


  5 in total

1.  Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalized with COVID-19 during the First Five Waves of the Pandemic in Pakistan; Findings and Implications.

Authors:  Kiran Ramzan; Sameen Shafiq; Iqra Raees; Zia Ul Mustafa; Muhammad Salman; Amer Hayat Khan; Johanna C Meyer; Brian Godman
Journal:  Antibiotics (Basel)       Date:  2022-06-09

2.  COVID-19 and the rising scourge of antimicrobial resistance: A perspective from Pakistan.

Authors:  Fatima Faraz; Mohammad Ebad Ur Rehman; Aiza Iqbal; Ayesha Azeem
Journal:  Ann Med Surg (Lond)       Date:  2022-07-31

3.  Potential impact of COVID-19 pandemic on escalating antimicrobial resistance in Pakistan.

Authors:  Muhammad Suleman Rana; Muhammad Usman; Muhammad Salman; Muhammad Masroor Alam; Aamer Ikram; Massab Umair; Rani Faryal; Muhammad Anas; Mehmood Qadir
Journal:  J Infect       Date:  2021-07-28       Impact factor: 38.637

4.  Genomic Epidemiology of SARS-CoV-2 Divulge B.1, B.1.36, and B.1.1.7 as the Most Dominant Lineages in First, Second, and Third Wave of SARS-CoV-2 Infections in Pakistan.

Authors:  Atia Basheer; Imran Zahoor
Journal:  Microorganisms       Date:  2021-12-17

5.  Prescription Patterns of Drugs Given to Hospitalized COVID-19 Patients: A Cross-Sectional Study in Colombia.

Authors:  Luis Fernando Valladales-Restrepo; Jaime Andrés Giraldo-Correa; Brayan Stiven Aristizábal-Carmona; Camilo Alexander Constain-Mosquera; Alejandra Sabogal-Ortiz; Jorge Enrique Machado-Alba
Journal:  Antibiotics (Basel)       Date:  2022-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.